KRAS and neoplasm: In selected cases enrichment of cancer gene mutations, such as copy number gain of MYC and KRAS, and pathogenic variants of IDH1 and STK11, was observed in residual tumor cells following study therapy (Fig. 4c and Supplementary Fig. 3).